SJS Investment Consulting’s Opus Genetics IRD Stock Holding History

SJS Investment Consulting’s Portfolio IRD Stock Details IRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.82K	Buy	+583	New	+$2.42K	﹤0.01%	2049

Other funds holding IRD

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Miller Financial Services Marshall, Michigan $132M AUM 10.64% 1-Year Est. Return

Empirical Wealth Management Seattle, Washington $7.38B AUM 22.9% 1-Year Est. Return

James Investment Research Alpha, Ohio $936M AUM 24.49% 1-Year Est. Return

SJS Investment Consulting's IRD Position: Q3 2026 in Review

SJS Investment Consulting opened a new position in Opus Genetics (IRD) in Q3 2026: 583 shares worth $2.82K. The stake represents ﹤0.01% of the portfolio and ranks #2049 among its holdings.

30 funds tracked by Wall St. Rank hold IRD as of Q3 2026.

SJS Investment Consulting held 583 shares of Opus Genetics worth $2.82K as of Q3 2026.
Opus Genetics was a new SJS Investment Consulting position in Q3 2026.
Opus Genetics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q3 2026, its #2049 holding.
30 funds tracked by Wall St. Rank held Opus Genetics as of Q3 2026.

Based on SJS Investment Consulting's 13F filing for Q3 2026, filed 26 Oct 2026.